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parallel, something complementary
to what takes place in pharma.
How so? The emergence of
chemical biology in universities
and medical schools reflects a
transition towards the integration
of small molecule synthesis, small
molecule screens and informatics
with the goal of illuminating
principles that underlie biology and
disease. This is not drug discovery,
but the resulting concepts and
technologies can be incorporated
by the pharmaceutical industry into
their drug discovery process. For
example, such efforts have already
identified many previously
unrecognized therapeutic targets
whose activities can be modulated
by small molecules — information
that can be exploited by the
pharmaceutical industry.
Will the ‘gulf’ between chemists
and biologists, to which Arthur
Kornberg famously referred,
interfere with these ambitions?
Possibly, as so much still needs to
be accomplished and the gulf still
exists. To advance our
understanding of disease biology,
we need chemists to populate
‘chemical descriptor space’
beyond that occupied traditionally
by drugs, yielding diverse small
molecules that disrupt
protein–protein interactions,
enhance binding specificity, and
modulate targets previously
thought to be ‘non-druggable’. We
need to unleash the awesome
creativity of biologists in a disease-
relevant and small molecule-based
context. But creating a social
structure where chemists are eager
to use their skills to follow-up on
biologists’ discoveries is vitally
important. The participation of
chemists prior to the start of the
screening process develops an
environment in which the chemists
are excited to participate with
biologists in efforts to optimize the
properties of the hits discovered in
screens, thereby moving them
towards more effective disease
probes or even drugs. 
Any other relevant sociologic
issues? I think so. For example,
there are operational and cultural
issues that distinguish academic
research from research performed
in the pharma industry.
Operationally, academic biologists
tend to tinker with candidate
assays, a trial-and-error process
that requires ready, hands-on
access to a minimal set of
screening equipment and
expertise. Much of the work is
performed in a pilot mode, rather
than the large-scale but more
limited-in-scope mode often used
in industry. Culturally, academic
biologists are more apt to create
new screening paradigms than to
adopt those used in drug discovery
in industry. Examples include the
use of matrix screening datasets to
create signatures of cell states, and
the use of state-switching assays.
Academic screening centers differ
from their industrial counterparts.
Is this another example of ‘big’
biology? Not really. Biology in all
sizes benefits from the tools and
concepts being developed by
chemical biology, just as all sizes
of biology labs have benefited from
DNA sequencing efforts. Some
projects are best done on a large
scale, while others are best done
on a small scale.
With so many hurdles to over-
come, are there reasons to be
optimistic? Certainly. Biologists
are moving to a more quantitative
mindset with which chemists are
inherently comfortable. Chemists’
exposure to more biology-driven
projects is providing a vehicle to
explore new facets of our field. The
fearless young generation appears
eager to bridge not only the gulf
between biology and chemistry,
but also those between biology
and mathematics, computer
science and other physical
sciences. They are our source of
great hope.
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What are they? Claudins are a
24-gene family of integral
membrane proteins. Members of
the claudin family range in size
from 20 to 27 kDa and are
predicted to have four
transmembrane-spanning
domains with cytoplasmic amino
and carboxyl termini. The carboxyl
termini of some claudins interact
with PDZ-domain-containing
peripheral membrane proteins and
other cytoplasmic proteins. The
manner of lateral and apposing
membrane (claudin–claudin) and
other (claudin–X) interactions,
combinatorial aspects, and
stoichiometry have yet to be
determined.
Where do they localize?
Claudins are found in the tight
junction at the interface of the
basolateral and apical membranes
of polarized epithelial and
endothelial cells, and also at
paranodes in compact myelin.
Transfected claudins are capable
of forming tight junction ‘strands’
or ‘fibrils’, the freeze–fracture
descriptions of a branching and
anastomosing network of rows of
intramembranous particles
characteristic of tight junctions.
Claudins are also found in the
basolateral membranes, possibly
as precursors to the fibrils. 
What do they do? The
extracellular domains of claudins
in one cell are thought to interact
with those in an apposing cell to
form a new class of ion channel
(see Figure 1). These channels
confer ion selectivity to the
paracellular pathway between
luminal and basolateral
extracellular compartments. The
permeability properties of the
paracellular pathway have the
biophysical characteristics of
conventional ion channels,
including ion selectivity,
anomalous mole fraction effects,
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pH dependence and a diameter
of ~6 Å. Exchanging the first
extracellular loop between
claudin-2 and claudin-4 changes
the Na+ and Cl– selectivities of
the paracellular pathway in
cultured epithelial cells. 
Aside from forming ion
channels, what else do
claudins do? Claudins and
occludin (also a four-pass
integral membrane protein)
interact laterally in the membrane
circumscribing the cell to form a
‘fence’. This barrier prevents the
diffusion of extracellularly facing
lipids between apical and
basolateral plasma membrane
domains. The tight junction may
also be an important component
of several signal transduction
pathways. For example, claudins
promote the activation of the
prodomain-containing form of the
matrix metalloproteinase MMP-2,
and have been implicated in the
b-catenin–Tcf/LEF signaling
pathway. Claudins may also
participate in vertebrate
morphogenesis, for example in
embryonic left–right axial
patterning.
Are they involved in disease?
Claudin-3 and claudin-4 serve as
Clostridium perfringens
enterotoxin receptors.
Additionally, claudin-4 is deleted
in patients with Williams–Beuren
syndrome, a neurodevelopmental
disorder affecting multiple
systems. Claudin-5 is deleted in
Velo-cardio-facial/DiGeorge
syndrome patients and claudin-5-
deficient mice show increased
leakage through the blood–brain
barrier. Mutations in claudin-14
are involved in hereditary
deafness, while mutations in
claudin-16 are associated with
hypomagnesemia. In addition,
claudins may play a role in
various cancers, because levels
of claudin-7 and claudin-23 were
found to decrease in ductal
carcinoma and intestinal-type
gastric cancer, respectively.
Similarly, claudin-1 was
downregulated in cases of
hereditary breast cancer.
However, increased expression
of claudin-1 and claudin-4 has
been observed in colorectal
cancer and pancreatic and
ovarian cancers, respectively.
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Chemical synapses provide the
predominant form of fast
functional information transfer
between neurons in the brain.
Synaptic transmission is initiated
in a presynaptic neuron when
neurotransmitter-containing
vesicles release their contents into
the synaptic cleft, which physically
separates the presynaptic and
postsynaptic neurons. The
released neurotransmitter
molecules then bind to their
cognate receptors on the
postsynaptic neuron, eliciting an
array of chemical and electrical
changes. Early physiological
studies made profound
contributions to our understanding
of the discrete (quantal) nature of
neurotransmitter release and its
calcium-dependence. Over the
past two decades, our knowledge
of synapse operation has been
advanced by molecular biological,
genetic and biochemical 
analyses (Box 1).
The presynaptic terminal,
located along the axon of most
neurons, is a compartment where
neurotransmitter-containing
vesicles cluster near a highly
specialized region of the plasma
membrane called the ‘active zone’.
From there, vesicles release their
contents during synaptic
transmission. There are exceptions
to this general architecture — for
example, presynaptic
specializations can occur in
dendrites rather than in axons and
there are synapses specialized for
continuous release that do not
have conventional active zones,
but have ‘ribbons’. Before
neurotransmitter release can occur
from a given release site, synaptic
vesicles must be sorted,
translocated to the active zone,
dock and be primed for fusion.
Synaptic vesicle recycling is an
integral feature of presynaptic
function, therefore, we have
chosen the synaptic vesicle cycle
as the central theme of this Primer.
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Figure 1.
The upper part of the figure shows an
apical/basal section of two interacting
plasma membranes at a tight junction.
The interacting membrane proteins
(claudins) separate the apical (a) from
the basolateral (bl) extracellular spaces.
A section perpendicular to the drawing
at one of the cell–cell interactions
reveals that the claudins (and occludin)
form a continuous linear polymer (lower
part of the figure), interrupting the exter-
nal leaflet of the lipid bilayer. The
claudins may interact between cells to
form a variety of ion-selective channels
(A, B or C) joining the two extracellular
spaces.
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